摘要
蛙皮素/胃泌素释放肽(BN / GRP)一类生长因子在恶性肿瘤的增殖和进展中起着至关重要的作用。针对胃泌素释放肽信号抑制剂已开发和测试的抗癌化合物显示出有前景的临床前和早期阶段的临床结果。在这篇综述中,我们将讨论的分子信号,表达和在不同的肿瘤模型中蛙皮素/胃泌素释放肽-促胃液素释放肽受体的功能作用,并且会将重点放在现有的战略针对蛙皮素/胃泌素释放肽-促胃液素释放肽受体癌症治疗以及肿瘤的诊断和跟踪。
关键词: 肿瘤,神经肽,信号转导,药物靶标,临床试验。
图形摘要
Current Drug Targets
Title:Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Volume: 17 Issue: 5
Author(s): Mikko O. Laukkanen and Maria Domenica Castellone
Affiliation:
关键词: 肿瘤,神经肽,信号转导,药物靶标,临床试验。
摘要: Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been developed and tested as anticancer compounds showing promising preclinical and early phase clinical results. In this review, we will discuss the molecular signaling, expression and the functional role of BN/GRP-GRPR in different cancer models and will focus on the available strategies to target BN/GRP-GRPR in cancer treatment as well as in tumour diagnosis and follow up.
Export Options
About this article
Cite this article as:
Mikko O. Laukkanen and Maria Domenica Castellone , Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666151001112130
DOI https://dx.doi.org/10.2174/1389450116666151001112130 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Development of Peptide and Protein Based Radiopharmaceuticals
Current Pharmaceutical Design Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews The ECL Cell: Relay Station for Gastric Integrity
Current Medicinal Chemistry Critical Aspects to be Considered Prior to Large-Scale Production of Peptides
Current Protein & Peptide Science Targeting Angiogenesis in Gastro-Intestinal Non Colorectal Cancers; A Review
Current Angiogenesis (Discontinued) MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Current Pharmaceutical Design Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs